Cambrex Cancels Second Quarter Earnings Conference Call and Will Not Update Financial Guidance
07 Août 2019 - 6:55PM
Cambrex Corporation (NYSE: CBM), the leading small molecule company
providing drug substance, drug product and analytical services
across the entire drug lifecycle, today announced that it will not
hold a second quarter 2019 earnings conference call and will not
update previously provided financial guidance given the pending
acquisition by an affiliate of the Permira funds.
About CambrexCambrex is the leading small
molecule company that provides drug substance, drug product and
analytical services across the entire drug lifecycle. The company
provides customers with an end-to-end partnership for the research,
development and manufacture of small molecule therapeutics. With
over 35 years’ experience and a growing team of over 2,000 experts
servicing global clients from sites in North America and Europe,
Cambrex is a trusted partner in branded and generic markets for API
and dosage form development and manufacturing.
Cambrex offers a range of specialist drug
substance technologies and capabilities including biocatalysis,
continuous flow, controlled substances, solid state science,
material characterization and highly potent APIs. In addition,
Cambrex can support conventional dosage forms including oral
solids, semi-solids and liquids and has the expertise to
manufacture specialist dosage forms such as modified-release, fixed
dose combination, pediatric, bi-layer tablets, stick packs,
topicals, controlled substances, sterile and non-sterile
ointments.
For more information, please visit
www.cambrex.com
Contact: |
Stephanie LaFiuraInvestor Relations AssociateTel:
201-804-3037Email: stephanie.lafiura@cambrex.com |
Cambrex (NYSE:CBM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cambrex (NYSE:CBM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Cambrex Corp (New York Stock Exchange): 0 recent articles
Plus d'articles sur